Cognition Therapeutics (CGTX) Financials

Cognition Therapeutics logo
$0.58 -0.02 (-3.06%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.57 -0.01 (-1.24%)
As of 11/20/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Cognition Therapeutics

Annual Income Statements for Cognition Therapeutics

This table shows Cognition Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-12 -16 -21 -26 -34 -23
Consolidated Net Income / (Loss)
-7.84 -12 -21 -26 -34 -23
Net Income / (Loss) Continuing Operations
-7.84 -12 -21 -26 -34 -24
Total Pre-Tax Income
-7.84 -12 -21 -26 -34 -24
Total Operating Income
-17 -29 -44 -51 -54 -48
Total Gross Profit
11 15 0.00 0.00 0.00 0.00
Total Revenue
11 15 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
17 29 44 51 54 48
Selling, General & Admin Expense
4.52 10 13 14 12 11
Research & Development Expense
13 19 30 37 42 37
Total Other Income / (Expense), net
-1.29 1.67 22 25 20 24
Interest & Investment Income
- - - -0.03 -0.03 -0.01
Other Income / (Expense), net
0.59 2.12 22 25 20 24
Basic Earnings per Share
($23.76) ($3.13) ($0.91) ($0.86) ($0.86) ($0.32)
Weighted Average Basic Shares Outstanding
508.11K 5.19M 23.64M 30.03M 39.73M 72.77M
Diluted Earnings per Share
($23.76) ($3.13) ($0.91) ($0.86) ($0.86) ($0.32)
Weighted Average Diluted Shares Outstanding
508.11K 5.19M 23.64M 30.03M 39.73M 72.77M
Weighted Average Basic & Diluted Shares Outstanding
- 22.58M 29.26M 39.00M 61.97M 89.35M

Quarterly Income Statements for Cognition Therapeutics

This table shows Cognition Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-9.15 -7.04 -9.94 -7.84 -8.49 -6.74 -4.93 -3.34 -4.58 -3.94 -4.15
Consolidated Net Income / (Loss)
-9.15 -7.04 -9.94 -7.84 -8.49 -6.74 -4.93 -3.34 -4.58 -3.94 -4.15
Net Income / (Loss) Continuing Operations
-9.16 -7.05 -9.94 -7.85 -8.49 -6.74 -4.93 -3.35 -4.58 -3.94 -4.15
Total Pre-Tax Income
-9.16 -7.05 -9.94 -7.85 -8.49 -6.74 -4.93 -3.35 -4.58 -3.94 -4.15
Total Operating Income
-14 -15 -14 -11 -14 -14 -6.38 -14 -8.82 -7.74 -7.38
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
14 15 14 11 14 14 6.38 14 8.82 7.74 7.38
Selling, General & Admin Expense
3.55 3.10 3.07 2.57 2.99 2.50 2.60 2.52 2.70 2.64 2.25
Research & Development Expense
11 12 11 8.15 11 11 3.77 11 6.12 5.10 5.12
Total Other Income / (Expense), net
4.94 7.63 4.52 2.88 5.29 7.24 1.45 10 4.24 3.80 3.23
Interest & Investment Income
-0.01 -0.01 -0.00 -0.01 -0.01 -0.00 1.22 -0.01 -0.01 -0.00 -0.00
Other Income / (Expense), net
4.95 7.64 4.53 2.88 5.30 7.24 0.23 10 4.25 3.81 3.23
Basic Earnings per Share
($0.27) ($0.18) ($0.25) ($0.16) ($0.14) ($0.11) ($0.06) ($0.01) ($0.05) ($0.04) ($0.04)
Weighted Average Basic Shares Outstanding
33.74M 40.06M 40.42M 39.73M 61.83M 63.69M 77.95M 72.77M 89.19M 90.62M 95.10M
Diluted Earnings per Share
($0.27) ($0.18) ($0.25) ($0.16) ($0.14) ($0.11) ($0.06) ($0.01) ($0.05) ($0.04) ($0.04)
Weighted Average Diluted Shares Outstanding
33.74M 40.06M 40.42M 39.73M 61.83M 63.69M 77.95M 72.77M 89.19M 90.62M 95.10M
Weighted Average Basic & Diluted Shares Outstanding
40.06M 40.13M 41.55M 61.97M 61.99M 73.47M 88.27M 89.35M 89.50M 95.09M 95.10M

Annual Cash Flow Statements for Cognition Therapeutics

This table details how cash moves in and out of Cognition Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
2.30 50 -13 -12 -4.91 12
Net Cash From Operating Activities
-3.43 -3.63 -19 -16 -28 -25
Net Cash From Continuing Operating Activities
-3.43 -3.63 -19 -16 -28 -25
Net Income / (Loss) Continuing Operations
-7.84 -12 -21 -26 -34 -23
Consolidated Net Income / (Loss)
-7.84 -12 -21 -26 -34 -23
Depreciation Expense
0.10 0.09 0.08 0.10 0.11 0.04
Amortization Expense
0.84 0.38 0.15 0.16 0.16 0.19
Non-Cash Adjustments To Reconcile Net Income
2.70 5.74 1.70 7.06 2.54 -5.11
Changes in Operating Assets and Liabilities, net
0.77 1.87 0.93 2.46 2.69 3.78
Net Cash From Investing Activities
-0.01 -0.03 -0.17 -0.15 -0.00 0.01
Net Cash From Continuing Investing Activities
-0.01 -0.03 -0.17 -0.15 -0.00 0.01
Purchase of Property, Plant & Equipment
-0.01 -0.03 -0.17 -0.15 -0.00 0.00
Sale of Property, Plant & Equipment
- - - - 0.00 0.01
Net Cash From Financing Activities
5.77 53 5.55 4.52 24 37
Net Cash From Continuing Financing Activities
5.77 53 5.55 4.52 24 37
Repayment of Debt
-0.10 -0.27 -1.40 -0.81 -0.74 -0.35
Issuance of Common Equity
0.00 44 5.32 5.33 24 37
Other Financing Activities, net
0.05 9.25 1.62 0.00 -0.05 -0.09

Quarterly Cash Flow Statements for Cognition Therapeutics

This table details how cash moves in and out of Cognition Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
4.75 -6.14 -6.52 3.00 -8.58 -4.87 28 -2.82 -5.78 3.54 -3.29
Net Cash From Operating Activities
-7.24 -6.00 -6.85 -8.38 -9.88 -5.62 -5.65 -3.44 -5.54 -3.05 -3.26
Net Cash From Continuing Operating Activities
-7.24 -6.00 -6.85 -8.38 -9.88 -5.62 -5.65 -3.44 -5.54 -3.03 -3.26
Net Income / (Loss) Continuing Operations
-9.15 -7.04 -9.94 -7.84 -8.48 -6.73 -4.93 -3.34 -4.57 -3.93 -4.15
Consolidated Net Income / (Loss)
-9.15 -7.04 -9.94 -7.84 -8.48 -6.73 -4.93 -3.34 -4.57 -3.93 -4.15
Depreciation Expense
0.03 0.03 0.03 0.03 -0.01 0.02 0.02 0.01 0.01 0.01 0.01
Amortization Expense
0.03 0.04 0.04 0.04 0.05 0.05 0.05 0.05 0.06 0.05 0.02
Non-Cash Adjustments To Reconcile Net Income
1.79 -1.16 0.70 1.22 -1.51 -0.89 4.91 -7.62 6.60 1.03 0.80
Changes in Operating Assets and Liabilities, net
0.06 2.14 2.32 -1.83 0.06 1.94 -5.69 7.47 -7.64 -0.18 0.06
Net Cash From Financing Activities
12 -0.14 0.33 11 1.30 0.75 34 0.61 -0.23 6.61 -0.03
Net Cash From Continuing Financing Activities
12 -0.14 0.33 11 1.30 0.75 34 0.61 -0.23 6.61 -0.03
Repayment of Debt
-0.18 -0.18 -0.19 -0.20 -0.12 -0.12 -0.04 -0.07 -0.11 -0.12 -0.08
Issuance of Common Equity
12 - 0.50 12 1.46 0.88 34 0.75 0.00 6.74 0.05

Annual Balance Sheets for Cognition Therapeutics

This table presents Cognition Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
7.12 59 50 35 30 48
Total Current Assets
6.91 59 48 34 30 48
Cash & Equivalents
5.19 55 42 30 25 37
Restricted Cash
- - - - 0.00 0.19
Prepaid Expenses
0.54 2.01 2.41 3.02 1.86 1.07
Other Current Assets
0.59 1.80 3.67 1.28 2.69 9.92
Plant, Property, & Equipment, net
0.21 0.15 0.23 0.28 0.18 0.09
Total Noncurrent Assets
0.00 0.00 2.55 0.66 0.50 0.31
Other Noncurrent Operating Assets
- 0.00 2.55 0.66 0.50 0.31
Total Liabilities & Shareholders' Equity
7.12 59 50 35 30 48
Total Liabilities
20 7.86 10 11 11 14
Total Current Liabilities
3.25 7.86 7.80 10 11 14
Accounts Payable
2.00 4.17 3.22 3.70 1.98 1.12
Accrued Expenses
0.99 1.75 2.09 4.06 7.62 12
Current Deferred Revenue
- 0.75 1.70 1.70 1.07 0.37
Other Current Liabilities
0.25 1.19 0.78 0.72 0.47 0.44
Total Noncurrent Liabilities
17 0.00 2.38 0.52 0.34 0.20
Other Noncurrent Operating Liabilities
3.83 0.00 2.38 0.52 0.34 0.20
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-68 51 40 24 19 34
Total Preferred & Common Equity
-68 51 40 24 19 34
Preferred Stock
- 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-68 51 40 24 19 34
Common Stock
0.22 145 156 166 194 233
Retained Earnings
-68 -94 -115 -141 -175 -199

Quarterly Balance Sheets for Cognition Therapeutics

This table presents Cognition Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
39 39 34 28 24 20 43 36 39 35
Total Current Assets
36 38 34 27 23 19 43 36 38 34
Cash & Equivalents
33 35 29 22 16 11 39 31 34 31
Restricted Cash
- - - - - 0.81 0.49 0.10 0.75 0.72
Prepaid Expenses
1.43 2.44 1.92 1.45 1.66 1.21 1.16 0.93 0.59 0.26
Other Current Assets
1.64 0.86 3.10 3.37 4.78 6.29 1.90 3.66 2.95 2.50
Plant, Property, & Equipment, net
0.28 0.26 0.23 0.21 0.19 0.17 0.16 0.08 0.09 0.08
Total Noncurrent Assets
2.45 0.63 0.59 0.54 0.44 0.40 0.35 0.25 0.51 0.49
Other Noncurrent Operating Assets
2.45 0.63 0.59 0.54 0.44 0.40 0.35 0.25 0.51 0.49
Total Liabilities & Shareholders' Equity
39 39 34 28 24 20 43 36 39 35
Total Liabilities
9.85 9.99 11 13 11 13 6.87 6.23 5.87 5.53
Total Current Liabilities
8.23 9.50 11 13 11 12 6.65 6.05 5.45 5.13
Accounts Payable
2.86 2.64 3.03 1.90 1.82 0.77 0.83 3.85 0.67 0.45
Accrued Expenses
4.29 4.73 6.06 9.51 7.71 9.37 3.92 1.69 3.83 3.88
Current Deferred Revenue
0.91 1.58 1.45 1.12 1.07 1.98 1.74 0.22 0.78 0.72
Other Current Liabilities
0.17 0.55 0.37 0.19 0.36 0.24 0.17 0.29 0.17 0.09
Total Noncurrent Liabilities
1.62 0.49 0.44 0.39 0.28 0.23 0.21 0.18 0.42 0.40
Other Noncurrent Operating Liabilities
1.62 0.49 0.44 0.39 0.28 0.23 0.21 0.18 0.42 0.40
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
29 29 23 14 12 7.03 37 30 33 29
Total Preferred & Common Equity
29 29 23 14 12 7.03 37 30 33 29
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
29 29 23 14 12 7.03 37 30 33 29
Common Stock
162 179 180 182 196 197 232 233 240 241
Retained Earnings
-133 -150 -157 -167 -184 -190 -195 -203 -207 -211

Annual Metrics And Ratios for Cognition Therapeutics

This table displays calculated financial ratios and metrics derived from Cognition Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 22,036,382.00 23,971,042.00 30,417,082.00 41,547,995.00 88,274,258.00
DEI Adjusted Shares Outstanding
0.00 22,036,382.00 23,971,042.00 30,417,082.00 41,547,995.00 88,274,258.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -0.74 -0.89 -0.85 -0.82 -0.27
Growth Metrics
- - - - - -
Revenue Growth
0.00% 40.13% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% -63.73% 18.61% -20.67% -31.99% 30.99%
EBIT Growth
0.00% -57.47% 19.19% -20.52% -31.73% 30.86%
NOPAT Growth
0.00% -64.29% -52.29% -16.47% -6.39% 11.43%
Net Income Growth
0.00% -49.46% -82.63% -20.52% -31.73% 30.86%
EPS Growth
0.00% 86.83% 70.93% 5.49% 0.00% 62.79%
Operating Cash Flow Growth
0.00% -5.77% -410.41% 13.57% -77.76% 13.65%
Free Cash Flow Firm Growth
0.00% 0.00% -50.18% 3.83% -17.83% -0.07%
Invested Capital Growth
0.00% 33.06% 61.92% -314.93% -14.89% 56.40%
Revenue Q/Q Growth
0.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% 30.07% -13.01% 0.89% 16.18%
EBIT Q/Q Growth
0.00% 0.00% 29.75% -12.90% 0.87% 16.08%
NOPAT Q/Q Growth
0.00% 0.00% 5.45% -13.13% 7.64% -6.57%
Net Income Q/Q Growth
0.00% 0.00% 9.16% -12.96% 0.87% 16.08%
EPS Q/Q Growth
0.00% 0.00% -108.51% -8.86% 11.34% 31.91%
Operating Cash Flow Q/Q Growth
0.00% 13.79% -124.70% 22.79% -11.45% 16.74%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 9.41% 1.21% -3.81%
Invested Capital Q/Q Growth
0.00% 0.00% 81.99% -34.75% 16.87% 17.15%
Profitability Metrics
- - - - - -
Gross Margin
100.00% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
-146.29% -170.94% 0.00% 0.00% 0.00% 0.00%
Operating Margin
-160.36% -188.01% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
-154.90% -174.06% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
-72.22% -77.02% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 99.87% 99.90% 99.93% 99.94%
Interest Burden Percent
46.62% 44.25% 100.13% 100.10% 100.07% 100.06%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
61.18% -60.93% -46.76% -79.69% -157.19% -88.60%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-236.18% -79.92% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-110.11% -35.37% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
325.52% 26.79% -46.76% -79.69% -157.19% -88.60%
Return on Equity Simple (ROE_SIMPLE)
11.50% -22.85% -53.16% -105.37% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-12 -20 -30 -36 -38 -33
NOPAT Margin
-112.25% -131.61% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-56.71% 35.29% 18.88% 27.19% 13.85% 32.16%
Return On Investment Capital (ROIC_SIMPLE)
- - - -145.08% -201.47% -97.63%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
41.64% 65.91% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
118.72% 122.10% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
160.36% 188.01% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-17 -26 -21 -26 -34 -23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-16 -26 -21 -26 -34 -23
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 2.72 1.25 2.30 1.55 3.48
Price to Tangible Book Value (P/TBV)
0.00 2.72 1.25 2.30 1.55 3.48
Price to Revenue (P/Rev)
4.17 9.16 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
9.97 5.56 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
-1.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
-1.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.60 -1.22 -1.05 -1.10 -1.27 -1.17
Leverage Ratio
-0.56 1.72 1.20 1.32 1.51 1.48
Compound Leverage Factor
-0.26 0.76 1.20 1.32 1.51 1.48
Debt to Total Capital
33,821.05% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
33,821.05% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
145,710.53% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-179,431.58% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
-0.81 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
-0.48 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
-0.81 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-1.05 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
-0.63 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
-1.05 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-17.71 8.22 -0.69 -4.06 -9.57 -1.44
Noncontrolling Interest Sharing Ratio
-432.11% 143.97% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
2.13 7.50 6.11 3.37 2.65 3.45
Quick Ratio
1.78 7.02 5.33 2.94 2.24 2.64
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -22 -33 -31 -37 -37
Operating Cash Flow to CapEx
-34,330.00% -13,448.15% -10,838.01% -10,896.60% -711,850.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 -48.27 -1,165.03 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-1.83 -8.07 -661.89 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-1.83 -8.13 -668.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - -
Asset Turnover
1.52 0.46 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
18.46 28.84 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
51.45 85.46 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
19.77 12.66 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
19.77 12.66 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - -
Invested Capital
-5.15 -3.45 -1.31 -5.45 -6.26 -2.73
Invested Capital Turnover
-2.11 -3.54 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 1.70 2.14 -4.14 -0.81 3.53
Enterprise Value (EV)
108 85 8.78 26 4.13 82
Market Capitalization
45 139 50 56 29 119
Book Value per Share
($134.19) $2.33 $1.68 $0.80 $0.45 $0.39
Tangible Book Value per Share
($134.19) $2.33 $1.68 $0.80 $0.45 $0.39
Total Capital
0.04 51 40 24 19 34
Total Debt
13 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
13 0.00 0.00 0.00 0.00 0.00
Net Debt
7.66 -55 -42 -30 -25 -37
Capital Expenditures (CapEx)
0.01 0.03 0.17 0.15 0.00 -0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.53 -3.59 -1.71 -5.87 -6.60 -2.93
Debt-free Net Working Capital (DFNWC)
3.66 51 40 24 18 34
Net Working Capital (NWC)
3.66 51 40 24 18 34
Net Nonoperating Expense (NNE)
-4.35 -8.30 -9.09 -9.72 -3.81 -9.97
Net Nonoperating Obligations (NNO)
7.66 -55 -42 -30 -25 -37
Total Depreciation and Amortization (D&A)
0.93 0.48 0.24 0.25 0.27 0.23
Debt-free, Cash-free Net Working Capital to Revenue
-14.10% -23.62% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
33.70% 336.13% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
33.70% 336.13% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($3.13) ($0.91) ($0.86) ($0.86) ($0.32)
Adjusted Weighted Average Basic Shares Outstanding
0.00 5.19M 23.64M 30.03M 39.73M 72.77M
Adjusted Diluted Earnings per Share
$0.00 ($3.13) ($0.91) ($0.86) ($0.86) ($0.32)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 5.19M 23.64M 30.03M 39.73M 72.77M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 22.58M 29.26M 39.00M 61.97M 89.35M
Normalized Net Operating Profit after Tax (NOPAT)
-12 -20 -30 -36 -38 -33
Normalized NOPAT Margin
-112.25% -131.61% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
-72.22% -77.02% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
-8.94 -58.84 -764.18 0.00 0.00 0.00
NOPAT to Interest Expense
-6.48 -44.49 -1,088.78 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-8.95 -58.90 -770.29 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-6.49 -44.55 -1,094.88 0.00 0.00 0.00
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Cognition Therapeutics

This table displays calculated financial ratios and metrics derived from Cognition Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
39,000,152.00 40,058,498.00 40,132,961.00 41,547,995.00 61,972,946.00 61,993,046.00 73,472,199.00 88,274,258.00 89,353,773.00 89,498,015.00 95,093,746.00
DEI Adjusted Shares Outstanding
39,000,152.00 40,058,498.00 40,132,961.00 41,547,995.00 61,972,946.00 61,993,046.00 73,472,199.00 88,274,258.00 89,353,773.00 89,498,015.00 95,093,746.00
DEI Earnings Per Adjusted Shares Outstanding
-0.23 -0.18 -0.25 -0.19 -0.14 -0.11 -0.07 -0.04 -0.05 -0.04 -0.04
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-48.77% -49.50% -47.62% 3.76% 7.24% 4.32% 50.65% 57.77% 46.63% 41.90% 32.43%
EBIT Growth
-48.27% -48.98% -47.24% 3.67% 7.33% 4.36% 50.39% 57.37% 46.11% 41.61% 32.56%
NOPAT Growth
-57.16% -24.21% 1.91% 29.40% 2.32% 4.77% 55.92% -27.49% 35.99% 44.64% -15.72%
Net Income Growth
-48.27% -48.98% -47.24% 3.67% 7.28% 4.36% 50.39% 57.37% 46.08% 41.59% 15.92%
EPS Growth
-28.57% -12.50% -13.64% 40.74% 48.15% 38.89% 76.00% 93.75% 64.29% 63.64% 33.33%
Operating Cash Flow Growth
-167.80% -62.26% -64.65% -53.63% -36.35% 6.24% 17.52% 59.00% 43.89% 45.71% 42.33%
Free Cash Flow Firm Growth
-17.67% -2.93% 51.08% -3.04% -59.37% -42.70% -31.02% -95.66% 20.18% 23.88% 28.03%
Invested Capital Growth
-91.97% -97.00% -86.22% -14.89% 28.45% 18.03% 56.25% 56.40% 68.40% 61.62% 33.27%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-12.61% 23.30% -41.48% 21.24% -8.54% 20.89% 27.03% 32.59% -37.17% 13.88% -6.04%
EBIT Q/Q Growth
-12.41% 23.06% -41.13% 21.08% -8.14% 20.59% 26.79% 32.19% -36.70% 13.96% -5.39%
NOPAT Q/Q Growth
7.16% -4.08% 1.46% 25.86% -28.46% -1.47% 54.39% -114.45% 35.51% 12.24% 4.67%
Net Income Q/Q Growth
-12.41% 23.06% -41.13% 21.08% -8.20% 20.59% 26.79% 32.19% -36.85% 13.99% -5.34%
EPS Q/Q Growth
0.00% 33.33% -38.89% 36.00% 12.50% 21.43% 45.45% 83.33% -400.00% 20.00% 0.00%
Operating Cash Flow Q/Q Growth
-32.77% 17.21% -14.24% -22.35% -17.84% 43.07% -0.50% 39.18% -61.25% 44.91% -6.75%
Free Cash Flow Firm Q/Q Growth
-9.08% -6.59% 12.13% -0.86% -68.71% 4.56% 19.32% -50.61% 31.17% 8.98% 23.72%
Invested Capital Q/Q Growth
-6.66% 4.94% -36.30% 16.87% 33.57% -8.90% 27.25% 17.15% 51.85% -32.27% -26.47%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
99.89% 99.90% 99.97% 99.94% 100.00% 99.96% 100.00% 99.85% 100.00% 100.00% 100.00%
Interest Burden Percent
100.11% 100.10% 100.03% 100.06% 100.06% 100.04% 100.00% 100.15% 100.11% 100.08% 100.02%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-89.00% -108.31% -157.90% -157.19% -161.95% -219.68% -109.73% -88.60% -92.82% -83.76% -48.60%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-89.00% -108.31% -157.90% -157.19% -161.95% -219.68% -109.73% -88.60% -92.82% -83.76% -48.60%
Return on Equity Simple (ROE_SIMPLE)
-99.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-9.87 -10 -10 -7.51 -9.64 -9.78 -4.46 -9.57 -6.17 -5.42 -5.16
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
1.96% 9.84% 0.68% -1.22% 4.53% 15.22% -1.51% 20.08% 6.70% 6.40% 2.86%
Return On Investment Capital (ROIC_SIMPLE)
-34.20% -44.65% -69.91% -40.03% -78.59% -139.20% -12.22% -27.92% -20.63% -16.40% -17.64%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-9.15 -7.04 -9.94 -7.84 -8.48 -6.73 -4.93 -3.34 -4.57 -3.93 -4.14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-9.09 -6.97 -9.87 -7.77 -8.44 -6.67 -4.87 -3.28 -4.50 -3.88 -4.11
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.46 2.89 1.30 1.55 2.13 2.73 2.72 3.48 2.27 3.12 3.12
Price to Tangible Book Value (P/TBV)
2.46 2.89 1.30 1.55 2.13 2.73 2.72 3.48 2.27 3.12 3.12
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.14 -1.15 -1.27 -1.27 -1.24 -1.33 -1.21 -1.17 -1.13 -1.16 -1.08
Leverage Ratio
1.31 1.36 1.53 1.51 1.52 1.80 1.39 1.48 1.41 1.46 1.19
Compound Leverage Factor
1.31 1.37 1.53 1.51 1.52 1.80 1.39 1.49 1.42 1.46 1.19
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-1.05 -2.78 -8.21 -6.71 -10.13 -13.39 2.99 -0.07 -0.76 3.74 2.02
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.00 3.07 2.11 2.65 2.09 1.54 6.44 3.45 5.92 7.03 6.68
Quick Ratio
3.65 2.61 1.73 2.24 1.50 0.87 5.91 2.64 5.14 6.24 6.00
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-7.09 -7.55 -6.64 -6.70 -11 -11 -8.70 -13 -9.02 -8.21 -6.26
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% -838,200.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-5.81 -5.52 -7.53 -6.26 -4.16 -4.53 -3.29 -2.73 -1.31 -1.74 -2.20
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-2.78 -2.72 -3.49 -0.81 1.65 1.00 4.24 3.53 2.84 2.79 1.10
Enterprise Value (EV)
36 38 -3.20 4.13 9.65 7.65 59 82 37 68 60
Market Capitalization
71 66 19 29 26 19 99 119 68 103 91
Book Value per Share
$0.74 $0.57 $0.36 $0.45 $0.20 $0.11 $0.50 $0.39 $0.33 $0.37 $0.31
Tangible Book Value per Share
$0.74 $0.57 $0.36 $0.45 $0.20 $0.11 $0.50 $0.39 $0.33 $0.37 $0.31
Total Capital
29 23 14 19 12 7.03 37 34 30 33 29
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-35 -29 -22 -25 -16 -12 -40 -37 -31 -35 -31
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-6.21 -5.90 -7.89 -6.60 -4.51 -4.87 -3.59 -2.93 -1.46 -1.91 -2.36
Debt-free Net Working Capital (DFNWC)
28 23 14 18 12 6.69 36 34 30 33 29
Net Working Capital (NWC)
28 23 14 18 12 6.69 36 34 30 33 29
Net Nonoperating Expense (NNE)
-0.72 -3.23 -0.19 0.34 -1.16 -3.05 0.47 -6.23 -1.60 -1.48 -1.02
Net Nonoperating Obligations (NNO)
-35 -29 -22 -25 -16 -12 -40 -37 -31 -35 -31
Total Depreciation and Amortization (D&A)
0.06 0.07 0.07 0.07 0.05 0.06 0.06 0.06 0.07 0.06 0.03
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.27) ($0.18) ($0.25) ($0.16) ($0.14) ($0.11) ($0.06) ($0.01) ($0.05) ($0.04) ($0.04)
Adjusted Weighted Average Basic Shares Outstanding
33.74M 40.06M 40.42M 39.73M 61.83M 63.69M 77.95M 72.77M 89.19M 90.62M 95.10M
Adjusted Diluted Earnings per Share
($0.27) ($0.18) ($0.25) ($0.16) ($0.14) ($0.11) ($0.06) ($0.01) ($0.05) ($0.04) ($0.04)
Adjusted Weighted Average Diluted Shares Outstanding
33.74M 40.06M 40.42M 39.73M 61.83M 63.69M 77.95M 72.77M 89.19M 90.62M 95.10M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
40.06M 40.13M 41.55M 61.97M 61.99M 73.47M 88.27M 89.35M 89.50M 95.09M 95.10M
Normalized Net Operating Profit after Tax (NOPAT)
-9.87 -10 -10 -7.51 -9.64 -9.78 -4.46 -9.57 -6.17 -5.42 -5.16
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Cognition Therapeutics (NASDAQ: CGTX) remains a development-stage biotechnology company with no reported revenue. The company has generated quarterly net losses throughout the period provided, while research and development spending remains its largest operating expense. The latest statements show some improvement in quarterly expenses and cash resources, but CGTX continues to rely heavily on equity financing to fund operations.

  • Cash position improved in Q2 2026. Cash and equivalents rose to $34.0 million from $31.1 million in Q1 2026 and $10.7 million in Q2 2025. Including restricted cash, total cash resources were approximately $34.8 million.
  • Liquidity remains relatively strong compared with current obligations. Current assets of $38.3 million exceeded current liabilities of $5.5 million by a wide margin, implying a current ratio of roughly 7.0. Total liabilities were only $5.9 million versus $33.0 million of shareholders’ equity.
  • Quarterly operating expenses declined. Q2 2026 operating expenses fell to $7.7 million from $8.8 million in Q1 2026 and $14.0 million in the restated Q2 2025 period. Research and development expense declined to $5.1 million from $6.1 million sequentially and $11.5 million a year earlier.
  • Cash operating burn improved sequentially. Net cash used in operating activities was $3.1 million in Q2 2026, compared with $5.5 million in Q1 2026. This was also below the $5.6 million used in Q2 2025 and the $6.9 million used in Q2 2024.
  • Liabilities have generally decreased over the longer period. Total liabilities declined to $5.9 million in Q2 2026 from $12.6 million in Q2 2025 and $13.1 million in Q3 2024. The company also repaid $116,000 of debt during Q2.
  • Q2’s net loss narrowed but remained substantial. CGTX reported a net loss of $3.9 million, or $0.04 per share, compared with a $4.6 million loss, or $0.05 per share, in Q1 2026. However, the improvement was partly offset by $3.8 million of other income, while revenue remained zero.
  • Cash runway depends on future financing and spending. At the Q2 operating cash burn rate, the company’s cash balance appears capable of supporting operations for several quarters, but the runway could shorten if research spending increases or clinical development costs accelerate.
  • CGTX has not yet established commercial revenue. Reported revenue was $0 in each of the recent income statements provided. As a result, the company cannot currently fund research and development through operating sales.
  • Operating losses and negative operating cash flow remain persistent. The company posted a $7.7 million operating loss in Q2 2026 and has consistently used cash in operations across the reported quarters. Retained earnings reached a deficit of $207.1 million by June 30, 2026.
  • Equity financing has caused significant dilution. Q2 2026 included $6.7 million of cash from issuing common equity, following a $33.9 million equity raise in Q3 2025. Weighted-average basic shares increased to 90.6 million in Q2 2026 from 40.1 million in Q2 2024, reducing existing shareholders’ ownership percentage.

Overall, CGTX’s balance sheet is currently supported by a sizable cash position, low debt and improving expense levels. However, the investment case remains dependent on clinical and regulatory progress because the company has no revenue, continues to generate losses and has repeatedly relied on issuing shares to finance its operations.

11/22/26 07:41 AM ETAI Generated. May Contain Errors.

Cognition Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cognition Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Cognition Therapeutics' net income appears to be on a downward trend, with a most recent value of -$23.49 million in 2025, falling from -$7.84 million in 2020. The previous period was -$33.97 million in 2024. Find out what analysts predict for Cognition Therapeutics in the coming months.

Cognition Therapeutics' total operating income in 2025 was -$47.80 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $47.80 million

Over the last 5 years, Cognition Therapeutics' total revenue changed from $10.86 million in 2020 to $0.00 in 2025, a change of -100.0%.

In the past 12 quarters, Cognition Therapeutics' cash and equivalents has ranged from $10.74 million in Q2 2025 to $39.33 million in Q3 2025, and is currently $30.76 million as of their latest financial filing in Q3 2026.

Cognition Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2020.

Over the last 5 years, Cognition Therapeutics' book value per share changed from -134.19 in 2020 to 0.39 in 2025.



Financial statements for NASDAQ:CGTX last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners